UK markets closed

Northwest Biotherapeutics, Inc. (NWBO)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.4655-0.0145 (-3.02%)
At close: 03:59PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 562.41M
Enterprise value 609.01M
Trailing P/E 81.98
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)399.82
Price/book (mrq)N/A
Enterprise value/revenue 455.84
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) -0.64
52-week change 3-21.67%
S&P500 52-week change 326.49%
52-week high 31.0900
52-week low 30.4000
50-day moving average 30.5054
200-day moving average 30.6373

Share statistics

Avg vol (3-month) 31.64M
Avg vol (10-day) 31.86M
Shares outstanding 51.21B
Implied shares outstanding 61.21B
Float 81.1B
% held by insiders 19.18%
% held by institutions 10.05%
Shares short (30 Nov 2016) 414.14M
Short ratio (30 Nov 2016) 413.54
Short % of float (30 Nov 2016) 415.09%
Short % of shares outstanding (30 Nov 2016) 411.34%
Shares short (prior month 31 Oct 2016) 413.83M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:16
Last split date 326 Sept 2012

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-5,543.66%

Management effectiveness

Return on assets (ttm)-118.59%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)1.34M
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-67.70%
Gross profit (ttm)N/A
EBITDA -56.67M
Net income avi to common (ttm)-72.21M
Diluted EPS (ttm)-0.0700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.48M
Total cash per share (mrq)0
Total debt (mrq)49.08M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.08
Book value per share (mrq)-0.06

Cash flow statement

Operating cash flow (ttm)-54.8M
Levered free cash flow (ttm)-38.43M